

# PREVDUO® (neostigmine methylsulfate and glycopyrrolate) Injection—Prefilled Syringes



**Simplify Your Workflow**  
**Standard dosing ratio<sup>1</sup>**  
 for two FDA-approved products,  
 neostigmine methylsulfate and glycopyrrolate,  
**in one prefilled syringe**

**FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION PRODUCT AVAILABLE IN THE US<sup>2</sup>**

PREVDUO® is a registered trademark of Slayback Pharma LLC.

- ✓ Two-year shelf life<sup>3\*</sup> may offer enhanced inventory management
- ✓ Does not require compounding, diluting, mixing, or transferring, which may reduce waste<sup>4</sup>
- ✓ Aligns with medication strategies of ASHP Guidelines on Preventing Medication Errors in Hospitals<sup>4</sup>
- ✓ Compatible with automated dispensing machine system

\*When stored at the recommended storage condition of 20°C to 25°C (68°F to 77°F), protected from light. Store in carton before time of use.<sup>5</sup>

Product Name	NDC	Neostigmine Methylsulfate Concentration	Glycopyrrolate Concentration	Pack Size	Order Entry Number	
PREVDUO® (neostigmine methylsulfate and glycopyrrolate) Injection	42023-0269-05	3 mg/3 mL (1 mg/mL)	0.6 mg/3 mL (0.2 mg/mL)	5 x 3 mL Single-Dose Prefilled Syringes	Cencora	10280291
					Cardinal	5849005
					McKesson	2819167
					M&D	281584
					Henry Schein	143-8760
					McKesson Medical-Surgical	1232614

M&D: Morris & Dickson; NDC: National Drug Code.

Scan to  
learn more



# SIMPLIFYING YOUR PHARMACY WORKFLOW











## NO STEPS PRIOR WITH PREFILLED SYRINGE



Inject prescribed dosage intravenously

**VS**

## 10 STEPS USING STANDARD VIAL

 <p><b>1</b> Flip off cap of neostigmine vial</p>	 <p><b>2</b> Swab vial with isopropyl alcohol</p>	 <p><b>3</b> Withdraw appropriate amount of neostigmine</p>	 <p><b>4</b> Label syringe</p>	 <p><b>5</b> Inject intravenously</p>
 <p><b>6</b> Flip off cap of glycopyrrolate vial</p>	 <p><b>7</b> Swab vial with isopropyl alcohol</p>	 <p><b>8</b> Withdraw appropriate amount of glycopyrrolate</p>	 <p><b>9</b> Label syringe</p>	 <p><b>10</b> Inject intravenously</p>

## PREVDUO® (neostigmine methylsulfate and glycopyrrolate) Injection

**FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION PRODUCT AVAILABLE IN THE US<sup>2</sup>**



**References:** 1. Howard J, Wigley J, Rosen G, D'mello J. Glycopyrrolate: it's time to review. *J Clin Anesth.* 2017;36:51-53. 2. US Food and Drug Administration. Prescription and over-the-counter drug product list, 43rd edition. Cumulative Supplement Number 10: October 2023. <https://www.fda.gov/media/72973/download>. Accessed December 5, 2023. 3. Data on file. DOF-PRVD-01. Par Pharmaceutical, Inc.; July 20, 2023. 4. Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP guidelines on preventing medication errors in hospitals. *Am J Health-Syst Pharm.* 2018;75(19):1493-1517. 5. PREVDUO®. Prescribing Information. Par Pharmaceutical, Inc.

